|
| TABLE OF CONTENTS | ||||||||||||||||||||||||||||||||||||||||||||
 | ||||||||||||||||||||||||||||||||||||||||||||
| September 2013 Volume 10 Number 9 | ||||||||||||||||||||||||||||||||||||||||||||
| In this issue  Research HighlightsNews and ViewsReviewsPerspectives
| |||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
 | ||||||||||||||||||||||||||||||||||||||||||||
| Advertisement | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| NEWS AND VIEWS | Top | |||||||||||||||||||||||||||||||||||||||||||
| Prostate cancer: Prostate Health Index—improving screening in men with family history Stacy Loeb Published online: 13 August 2013 p497 | doi:10.1038/nrurol.2013.169 Although the optimal protocol of screening men for prostate cancer remains undefined, the Prostate Health Index—phi—might provide an additional tool to improve risk stratification, especially for men with a positive family history. Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Prostate cancer: AUA-ASTRO guidelines for post-RP radiation fail to go nuclear Alberto Bossi & Alberto Briganti Published online: 06 August 2013 p498 | doi:10.1038/nrurol.2013.163 A joint panel from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO) have issued their recommendations for the use of postprostatectomy radiation therapy. Although these guidelines are urgently needed, the AUA-ASTRO panel has failed to consider some salient points and the guidelines ultimately remain of little help. Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Bladder cancer: Is contrast-enhanced CT necessary for following up NMIBC? Mesut Remzi & Shahrokh F. Shariat Published online: 06 August 2013 p500 | doi:10.1038/nrurol.2013.170 Although patients with bladder cancer are at increased risk of developing upper tract urothelial carcinoma (UTUC), the overall incidence remains low. Serial CT urography is routinely performed in these patients to rule out UTUC, but its clinical value and cost-effectiveness are questionable, especially in patients with non-muscle-invasive disease. Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Prostate cancer: Should men with metastases undergo radical prostatectomy? Drew Moghanaki & Mitchell S. Anscher Published online: 16 July 2013 p501 | doi:10.1038/nrurol.2013.154 Circulating tumour cells might not only seed distant organs but also reseed the original cancer site, leading to accelerated tumour growth and decreased survival. A recent study suggests that radical prostatectomy might reduce the risk of reseeding and subsequent disease progression in patients with metastatic prostate cancer. Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| REVIEWS | Top | |||||||||||||||||||||||||||||||||||||||||||
| Management of combat-related urological trauma in the modern era Molly Williams & James Jezior Published online: 23 July 2013 p504 | doi:10.1038/nrurol.2013.148 Complex genitourinary injuries have emerged as common occurrences in current military combat operations. In this Review, the authors examine the current management strategies for combat-related injuries with specific focus on the lower urinary tract and genitalia. Abstract | Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Neuromodulation for overactive bladder Jamie Bartley, Jason Gilleran & Kenneth Peters Published online: 02 July 2013 p513 | doi:10.1038/nrurol.2013.143 Neuromodulation has emerged as a second-line treatment option for patients with overactive bladder (OAB) refractory to initial treatment. In this Review, the authors summarize the diagnosis and first-line treatment options for OAB before providing an in-depth discussion of neuromodulation. Abstract | Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Overview of the latest treatments for castration-resistant prostate cancer Mohamed Bishr & Fred Saad Published online: 25 June 2013 p522 | doi:10.1038/nrurol.2013.137 In this Review, Saad and Bishr present an overview of the different management approaches for patients with CRPC, paying particular attention to recently approved agents and therapies that have shown promising results in phase III trials. Abstract | Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Caveola-forming proteins caveolin-1 and PTRF in prostate cancer Zeyad D. Nassar, Michelle M. Hill, Robert G. Parton & Marie-Odile Parat Published online: 13 August 2013 p529 | doi:10.1038/nrurol.2013.168 Caveolae are flask-shaped invaginations of the plasma membrane involved in membrane trafficking and cell signalling. Here, Parat et al. discuss the roles of caveolin 1 and PTRF in prostate cancer, summarizing the available data on the expression and function of these caveola-forming proteins and asking whether they might be targeted for future therapeutic strategies. Abstract | Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| Toll-like receptors in urothelial cells—targets for cancer immunotherapy Helene LaRue, Cherifa Ayari, Alain Bergeron & Yves Fradet Published online: 27 August 2013 p537 | doi:10.1038/nrurol.2013.153 In this Review, LaRue et al. focus on the expression and role of toll-like receptors (TLRs) in normal and tumour urothelial cells and the potential use of TLR agonists for bladder cancer treatment. Abstract | Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
| PERSPECTIVES | Top | |||||||||||||||||||||||||||||||||||||||||||
| OPINION Prostatic fibrosis, lower urinary tract symptoms, and BPH Jose A. Rodriguez-Nieves & Jill A. Macoska Published online: 16 July 2013 p546 | doi:10.1038/nrurol.2013.149 In this Perspectives article, Rodriguez-Nieves and Macoska discuss relationships between prostatic tissue inflammation (from ageing, infection, or other inflammatory disease processes), prostatic tissue fibrosis, lower urinary tract dysfunction (LUTD), and BPH, as well as highlighting recent advances in the use of antifibrotic therapeutic agents for treating LUTD. Abstract | Full Text | PDF | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
Featured article:
| *Journal Citation Reports, Thomson, 2012. Nature Reviews Urology was previously published as Nature Clinical Practice Urology. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
 |
No comments:
Post a Comment